Ascletis Pharma Inc. ASCLF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score

31/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Ascletis Pharma Inc. (ASCLF) generated $-172.99M in operating cash flow for quarter ending 2025-06-30. After capital expenditures of $0.00, free cash flow was $-172.99M.

Free cash flow margin was -16002.8% of revenue. Cash conversion ratio was 1.97x, indicating earnings are backed by cash.

The company returned $12.8M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (62/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
INCOME (10/100) — Cash conversion ratio was 1.97x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

31/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

62/100

Proven by this page

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Ascletis Pharma Inc. Cash Flow History

Metric	TTM	Q2 FY2025	Q4 FY2024	Q2 FY2024	Q1 FY2024
Operating Cash Flow	$-514.57M	$-172.99M	$-138.16M	$-101.71M	$-101.71M
Capital Expenditure	$-2.1M	$0.00	$-2.1M	$0.00	$0.00
Free Cash Flow	$-516.66M	$-172.99M	$-140.26M	$-101.71M	$-101.71M